Preclinical models show that RAS(ON) inhibition alters the PDAC tumor microenvironment, suggesting T-cell involvement in responses.
Supplementary Figure S4: RAS(ON) multi-selective inhibition results in early changes to the PDAC tumor immune microenvironment
No takes yet. Share an insight, caveat, or question.
Orlen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: